CR20210077A - Nuevos compuestos heterocíclicos como inhibidores de la monoacilglicerol lipasa - Google Patents
Nuevos compuestos heterocíclicos como inhibidores de la monoacilglicerol lipasaInfo
- Publication number
- CR20210077A CR20210077A CR20210077A CR20210077A CR20210077A CR 20210077 A CR20210077 A CR 20210077A CR 20210077 A CR20210077 A CR 20210077A CR 20210077 A CR20210077 A CR 20210077A CR 20210077 A CR20210077 A CR 20210077A
- Authority
- CR
- Costa Rica
- Prior art keywords
- heterocyclic compounds
- new heterocyclic
- lipase inhibitors
- monoacylglycerol lipase
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
<p>La invención proporciona nuevos compuestos heterocíclicos que presentan la fórmula general (I) en donde A, L, X, m, n, R1 y R2 son como se describe en la presente, composiciones que incluyen los compuestos, procesos de fabricación de los compuestos y métodos de utilización de los compuestos.</p>
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18188681 | 2018-08-13 | ||
PCT/EP2019/071520 WO2020035424A1 (en) | 2018-08-13 | 2019-08-12 | New heterocyclic compounds as monoacylglycerol lipase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20210077A true CR20210077A (es) | 2021-03-11 |
Family
ID=63244467
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20210077A CR20210077A (es) | 2018-08-13 | 2019-08-12 | Nuevos compuestos heterocíclicos como inhibidores de la monoacilglicerol lipasa |
Country Status (22)
Country | Link |
---|---|
US (3) | US20200308190A1 (es) |
EP (1) | EP3837263A1 (es) |
JP (1) | JP2021534139A (es) |
KR (1) | KR20210045992A (es) |
CN (1) | CN112867720A (es) |
AR (1) | AR116666A1 (es) |
AU (1) | AU2019322538B2 (es) |
BR (1) | BR112021002298A2 (es) |
CA (1) | CA3104928A1 (es) |
CL (1) | CL2021000362A1 (es) |
CO (1) | CO2021002382A2 (es) |
CR (1) | CR20210077A (es) |
IL (1) | IL279173A (es) |
MA (1) | MA53219A (es) |
MX (1) | MX2021001433A (es) |
PE (1) | PE20211089A1 (es) |
PH (1) | PH12021500013A1 (es) |
RU (1) | RU2769507C1 (es) |
SG (1) | SG11202013064WA (es) |
TW (1) | TWI812770B (es) |
UA (1) | UA127629C2 (es) |
WO (1) | WO2020035424A1 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR114136A1 (es) | 2017-10-10 | 2020-07-29 | Hoffmann La Roche | Compuestos heterocíclicos |
CN111386269A (zh) | 2017-11-28 | 2020-07-07 | 豪夫迈·罗氏有限公司 | 新型杂环化合物 |
JP7269943B2 (ja) | 2018-01-08 | 2023-05-09 | エフ. ホフマン-ラ ロシュ アーゲー | Magl阻害剤としてのオクタヒドロピリド[1,2-アルファ]ピラジン |
CA3092470A1 (en) | 2018-02-27 | 2019-09-06 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors |
MA52940A (fr) | 2018-05-18 | 2021-04-28 | Incyte Corp | Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b |
BR112021002298A2 (pt) | 2018-08-13 | 2021-05-04 | F. Hoffmann-La Roche Ag | compostos heterocíclicos como inibidores da monoacilglicerol lipase |
TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
EP4043436A4 (en) * | 2019-09-05 | 2023-08-30 | Lunan Pharmaceutical Group Corporation | MAGL INHIBITOR, METHOD FOR PREPARATION AND USE |
US20210094971A1 (en) * | 2019-09-09 | 2021-04-01 | Hoffmann-La Roche Inc. | Heterocyclic compounds |
JP2022548028A (ja) * | 2019-09-12 | 2022-11-16 | エフ.ホフマン-ラ ロシュ アーゲー | Magl阻害剤としての4,4a,5,7,8,8a-ヘキサピリド[4,3-b][1,4]オキサジン-3-オン化合物 |
MX2022003023A (es) * | 2019-09-23 | 2022-04-07 | Hoffmann La Roche | Compuestos heterociclicos. |
EP4034538A1 (en) * | 2019-09-24 | 2022-08-03 | F. Hoffmann-La Roche AG | New heterocyclic monoacylglycerol lipase (magl) inhibitors |
WO2021058444A1 (en) * | 2019-09-24 | 2021-04-01 | F. Hoffmann-La Roche Ag | Heterocyclic compounds |
JOP20220085A1 (ar) * | 2019-10-07 | 2023-01-30 | De Shaw Res Llc | مركبات أريل ميثيلين حلقية غير متجانسة على هيئة حاصرات قناة بوتاسيوم Kv1.3 بجين شاكر |
US11512059B2 (en) * | 2020-03-26 | 2022-11-29 | Janssen Pharmaceutica Nv | Aminocyclobutanes as monoacylglycerol lipase modulators |
CN115989228A (zh) | 2020-09-03 | 2023-04-18 | 豪夫迈·罗氏有限公司 | 杂环化合物 |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5214038A (en) * | 1991-04-15 | 1993-05-25 | Hoechst-Roussel Pharmaceuticals Inc. | 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof |
US7160888B2 (en) | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
US7579495B2 (en) | 2003-12-19 | 2009-08-25 | Momentive Performance Materials Inc. | Active-releasing cyclic siloxanes |
CA2603322C (en) | 2005-03-31 | 2014-12-16 | Janssen Pharmaceutica N.V. | Bicyclic pyrazole compounds as antibacterial agents |
MX2007016523A (es) | 2005-06-20 | 2008-03-06 | Schering Corp | Piperidinas sustituidas ligadas a carbono y derivados de las mismas utiles como antagonistas de hsitamina h3. |
US8431695B2 (en) | 2005-11-02 | 2013-04-30 | Bayer Intellectual Property Gmbh | Pyrrolo[2,1-f][1,2,4]triazin-4-ylamines IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseases |
CA2637531A1 (en) | 2006-02-17 | 2007-08-30 | Memory Pharmaceuticals Corporation | Compounds having 5-ht6 receptor affinity |
WO2007117557A2 (en) | 2006-04-05 | 2007-10-18 | Vitae Pharmaceuticals, Inc. | Diaminopropanol renin inhibitors |
CN101796051B (zh) | 2007-03-12 | 2013-11-06 | 细胞内治疗公司 | 与取代的杂环稠合的γ-咔啉的合成 |
TW200942537A (en) | 2008-02-01 | 2009-10-16 | Irm Llc | Compounds and compositions as kinase inhibitors |
BRPI0919648A2 (pt) | 2008-10-29 | 2015-12-08 | Hoffmann La Roche | novos derivados de fenil amida ou piridil amida e seu uso como agonistas de gpbar1 |
BR112012005382A2 (pt) | 2009-09-10 | 2016-03-29 | Hoffmann La Roche | inibidores de jak |
WO2011059118A1 (ko) | 2009-11-10 | 2011-05-19 | Kim Hyun Jeen | 후각인지능력 검사 시스템 |
US9051296B2 (en) * | 2009-11-16 | 2015-06-09 | Raqualia Pharma Inc. | Aryl carboxamide derivatives as TTX-S blockers |
US8420661B2 (en) | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
CA2836311A1 (en) | 2011-05-16 | 2012-11-22 | Bionomics Limited | Amine derivatives as potassium channel blockers |
WO2013059118A1 (en) | 2011-10-19 | 2013-04-25 | The Trustees Of Columbia University In The City Of New York | Cyclopropenimine catalyst compositions and processes |
CN103958525A (zh) | 2011-11-30 | 2014-07-30 | 埃科特莱茵药品有限公司 | 3,7-二取代八氢-2H-吡啶并[4,3-e][1,3]噁嗪-2-酮抗生素 |
BR112014015103B1 (pt) | 2011-12-22 | 2022-06-28 | Novartis Ag | Derivados de di-hidro-benzo-oxazina e di-hidro-pirido-oxazina, seus usos, combinação e composição farmacêutica |
BR112014016672B1 (pt) | 2012-01-06 | 2022-06-28 | The Scripps Research Institute | Compostos de carbamato, composição farmaceutica e uso dos referidos compostos |
GB201209587D0 (en) | 2012-05-30 | 2012-07-11 | Takeda Pharmaceutical | Therapeutic compounds |
TW201422625A (zh) | 2012-11-26 | 2014-06-16 | Novartis Ag | 二氫-吡啶并-□衍生物之固體形式 |
ES2640482T3 (es) | 2013-04-16 | 2017-11-03 | Idorsia Pharmaceuticals Ltd | Derivados biaromáticos antibacterianos |
WO2016109501A1 (en) | 2014-12-30 | 2016-07-07 | Karos Pharmaceuticals, Inc. | Amide compounds as tryptophan hydroxylase inhibitors |
US10106556B2 (en) | 2015-03-30 | 2018-10-23 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
WO2016180536A1 (en) | 2015-05-13 | 2016-11-17 | Selvita S.A. | Substituted quinoxaline derivatives |
MX2017014714A (es) | 2015-05-21 | 2018-01-25 | Glaxosmithkline Ip Dev Ltd | Derivados de benzoimidazol como inhibidores de peptidil arginina deiminasa 4 (pad4). |
CA3014432C (en) | 2015-06-18 | 2024-05-07 | Cephalon, Inc. | Substituted 4-benzyl and 4-benzoyl piperidine derivatives |
US10323038B2 (en) | 2015-11-20 | 2019-06-18 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
WO2017087858A1 (en) | 2015-11-20 | 2017-05-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
CA3019298C (en) | 2016-03-31 | 2023-08-29 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
WO2017170830A1 (ja) | 2016-03-31 | 2017-10-05 | 武田薬品工業株式会社 | 複素環化合物 |
EA201990109A1 (ru) | 2016-06-30 | 2019-07-31 | Базилеа Фармацойтика Интернациональ Аг | Митохондриальные ингибиторы для лечения пролиферативных нарушений |
US10364255B2 (en) | 2017-06-12 | 2019-07-30 | Boehringer Ingleheim International Gmbh | Heteroaromatic compounds as Vanin inhibitors |
EP3689879A4 (en) | 2017-09-29 | 2021-07-14 | Takeda Pharmaceutical Company Limited | HETEROCYCLIC CONNECTION |
AR114136A1 (es) | 2017-10-10 | 2020-07-29 | Hoffmann La Roche | Compuestos heterocíclicos |
CN111386269A (zh) | 2017-11-28 | 2020-07-07 | 豪夫迈·罗氏有限公司 | 新型杂环化合物 |
TW201930300A (zh) | 2017-12-15 | 2019-08-01 | 瑞士商赫孚孟拉羅股份公司 | 新雜環化合物 |
JP7269943B2 (ja) | 2018-01-08 | 2023-05-09 | エフ. ホフマン-ラ ロシュ アーゲー | Magl阻害剤としてのオクタヒドロピリド[1,2-アルファ]ピラジン |
SI3768684T1 (sl) | 2018-03-22 | 2023-06-30 | F. Hoffmann - La Roche Ag | Zaviralci oksazin monoacilglicerol lipaze (MAGL) |
BR112021002298A2 (pt) | 2018-08-13 | 2021-05-04 | F. Hoffmann-La Roche Ag | compostos heterocíclicos como inibidores da monoacilglicerol lipase |
KR20210044217A (ko) | 2018-08-13 | 2021-04-22 | 에프. 호프만-라 로슈 아게 | 모노아실글리세롤 리파제 저해제로서의 신규 헤테로시클릭 화합물 |
AU2019383500A1 (en) | 2018-11-22 | 2021-05-27 | F. Hoffmann-La Roche Ag | New heterocyclic compounds |
CA3120499A1 (en) | 2018-11-22 | 2020-05-28 | Qilu Regor Therapeutics Inc. | Glp-1r agonists and uses thereof |
JP2022527590A (ja) | 2019-04-09 | 2022-06-02 | エフ.ホフマン-ラ ロシュ アーゲー | モノアシルグリセロールリパーゼ(magl)の阻害剤としての複素環式化合物 |
BR112021026820A2 (pt) | 2019-07-03 | 2022-02-22 | Hoffmann La Roche | Inibidores heterocíclicos de monoacilglicerol lipase (magl) |
CR20220004A (es) | 2019-07-09 | 2022-01-31 | Hoffmann La Roche | Nuevos compuestos heterocíclicos |
US20210094971A1 (en) | 2019-09-09 | 2021-04-01 | Hoffmann-La Roche Inc. | Heterocyclic compounds |
JP2022548028A (ja) | 2019-09-12 | 2022-11-16 | エフ.ホフマン-ラ ロシュ アーゲー | Magl阻害剤としての4,4a,5,7,8,8a-ヘキサピリド[4,3-b][1,4]オキサジン-3-オン化合物 |
EP4028402A1 (en) | 2019-09-12 | 2022-07-20 | F. Hoffmann-La Roche AG | Radiolabeled compounds |
MX2022003023A (es) | 2019-09-23 | 2022-04-07 | Hoffmann La Roche | Compuestos heterociclicos. |
EP4034538A1 (en) | 2019-09-24 | 2022-08-03 | F. Hoffmann-La Roche AG | New heterocyclic monoacylglycerol lipase (magl) inhibitors |
WO2021058443A1 (en) | 2019-09-24 | 2021-04-01 | F. Hoffmann-La Roche Ag | Fluorescent probes for monoacylglycerol lipase (magl) |
WO2021058444A1 (en) | 2019-09-24 | 2021-04-01 | F. Hoffmann-La Roche Ag | Heterocyclic compounds |
CN115989228A (zh) | 2020-09-03 | 2023-04-18 | 豪夫迈·罗氏有限公司 | 杂环化合物 |
-
2019
- 2019-08-12 BR BR112021002298-8A patent/BR112021002298A2/pt unknown
- 2019-08-12 UA UAA202101016A patent/UA127629C2/uk unknown
- 2019-08-12 MA MA053219A patent/MA53219A/fr unknown
- 2019-08-12 AU AU2019322538A patent/AU2019322538B2/en active Active
- 2019-08-12 WO PCT/EP2019/071520 patent/WO2020035424A1/en unknown
- 2019-08-12 PE PE2021000135A patent/PE20211089A1/es unknown
- 2019-08-12 CR CR20210077A patent/CR20210077A/es unknown
- 2019-08-12 SG SG11202013064WA patent/SG11202013064WA/en unknown
- 2019-08-12 RU RU2021106145A patent/RU2769507C1/ru active
- 2019-08-12 KR KR1020217004221A patent/KR20210045992A/ko active Search and Examination
- 2019-08-12 JP JP2021507457A patent/JP2021534139A/ja active Pending
- 2019-08-12 EP EP19755855.4A patent/EP3837263A1/en active Pending
- 2019-08-12 CN CN201980053749.3A patent/CN112867720A/zh active Pending
- 2019-08-12 CA CA3104928A patent/CA3104928A1/en active Pending
- 2019-08-12 MX MX2021001433A patent/MX2021001433A/es unknown
- 2019-08-13 TW TW108128734A patent/TWI812770B/zh active
- 2019-08-13 AR ARP190102303A patent/AR116666A1/es unknown
-
2020
- 2020-04-09 US US16/844,262 patent/US20200308190A1/en not_active Abandoned
- 2020-12-03 IL IL279173A patent/IL279173A/en unknown
-
2021
- 2021-02-10 CL CL2021000362A patent/CL2021000362A1/es unknown
- 2021-02-11 PH PH12021500013A patent/PH12021500013A1/en unknown
- 2021-02-24 CO CONC2021/0002382A patent/CO2021002382A2/es unknown
-
2022
- 2022-05-20 US US17/749,496 patent/US11802133B2/en active Active
-
2023
- 2023-09-26 US US18/475,065 patent/US20240150373A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230050901A1 (en) | 2023-02-16 |
MX2021001433A (es) | 2021-04-12 |
AR116666A1 (es) | 2021-06-02 |
SG11202013064WA (en) | 2021-01-28 |
PH12021500013A1 (en) | 2021-09-13 |
TWI812770B (zh) | 2023-08-21 |
US20240150373A1 (en) | 2024-05-09 |
AU2019322538A1 (en) | 2021-01-07 |
CO2021002382A2 (es) | 2021-03-08 |
TW202021970A (zh) | 2020-06-16 |
KR20210045992A (ko) | 2021-04-27 |
RU2769507C1 (ru) | 2022-04-01 |
UA127629C2 (uk) | 2023-11-08 |
AU2019322538B2 (en) | 2021-09-30 |
MA53219A (fr) | 2021-11-17 |
US11802133B2 (en) | 2023-10-31 |
CN112867720A (zh) | 2021-05-28 |
JP2021534139A (ja) | 2021-12-09 |
EP3837263A1 (en) | 2021-06-23 |
PE20211089A1 (es) | 2021-06-14 |
WO2020035424A1 (en) | 2020-02-20 |
IL279173A (en) | 2021-01-31 |
US20200308190A1 (en) | 2020-10-01 |
CA3104928A1 (en) | 2020-02-20 |
CL2021000362A1 (es) | 2021-07-09 |
BR112021002298A2 (pt) | 2021-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20210077A (es) | Nuevos compuestos heterocíclicos como inhibidores de la monoacilglicerol lipasa | |
PH12021500015A1 (en) | New heterocyclic compounds as monoacylglycerol lipase inhibitors | |
PH12021551167A1 (en) | New heterocyclic compounds | |
CR20200416A (es) | Nuevos compuestos heterocíclicos | |
MX2022002711A (es) | Nuevos inhibidores heterociclicos de monoacilglicerol lipasa (magl). | |
MX2021014441A (es) | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. | |
MX2021014443A (es) | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. | |
PH12017502090A1 (en) | Heterocyclic amides as kinase inhibitors | |
MX2021002978A (es) | Lactamas biciclicas y metodos de uso de las mismas. | |
MX2022002311A (es) | Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de monoacilglicerol lipasa (magl). | |
MX2018001430A (es) | Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca). | |
MX2018001890A (es) | Compuestos biciclicos como inhibidores de autotaxina (atx). | |
MX2022002831A (es) | Compuestos heterociclicos. | |
PH12019500664A1 (en) | New isoxazolyl ether derivatives as gaba a alpha5 pam | |
MX2022002554A (es) | Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de monoacilglicerol lipasa (magl). | |
MX2022000243A (es) | Nuevos compuestos heterociclicos. | |
MX2022003023A (es) | Compuestos heterociclicos. | |
MX2020009234A (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos. | |
MX2020013630A (es) | Analogos de rapamicina y usos de los mismos. | |
WO2018166993A3 (en) | PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | |
MX342311B (es) | Nuevos compuestos de azaespirodecanona como inhibidores de lipasa sensible a hormonas (hsl). | |
PH12021550320A1 (en) | Bicyclic heteroaryl derivatives | |
CR20210614A (es) | Nuevos inhibidores de egfr | |
MX2022006776A (es) | Composiciones farmaceuticas oftalmicas. | |
PH12018500406A1 (en) | Bicyclic compounds as atx inhibitors |